Bin Jiang

Bin Jiang

Auto-generated profile, based on publicly available information

Bin Jiang

Peking University International Hospital

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
SCShuchang Chen
Shuchang Chen
BJBin Jiang
Bin Jiang
WDWanming Da
Wanming Da
MGMing Gong
Ming Gong
MGMei Guan
Mei Guan
A multicenter prospective study was carried out to evaluate the efficacy of cyclosporin A (CsA) in 32 patients with myelodysplastic syndromes.The FAB subtypes of the patients included refractory...

2 August 2012 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
QJQian Jiang
Qian Jiang
XZXiang‐Yu Zhao
Xiang‐Yu Zhao
YQYa‐Zhen Qin
Ya‐Zhen Qin
Yanrong LiuYanrong Liu
Yanrong Liu
YLYue‐Yun Lai
Yue‐Yun Lai
Xiaojun HuangXiaojun Huang
Xiaojun Huang
Previous studies concerning BCR‐ABL mRNA levels by quantitative real‐time RT‐PCR (Q‐PCR) for chronic myelogenous leukemia (CML) have shown a significant concordance between peripheral blood (PB) and bone marrow (BM) assays. The objective of this study was to determine whether molecular monitoring using PB was comparable to using BM for CML. A comparative study was performed that analyzed the Q‐PCR results of 712 simultaneous PB and BM samples from 330 patients before and during imatinib therapy. For the 78 paired pretreatment samples, the level of BCR‐ABL mRNA in PB was lower than that in BM (P = 0.007). Although the overall amounts of BCR‐ABL mRNA in the PB and BM were comparable (P= 0.072) and there was a strong correlation (r = 0.839, P < 0.001) with the 634 paired on‐treatment samples, the depth of the molecular response in PB was lower than that in BM (P < 0.001). The level of BCR‐ABL mRNA in PB was lower than that in BM where the BM BCR‐ABL mRNA < 1 log reduction (P < 0.001) or ≥ 1–< 2 log‐reductions (P = 0.008) from the baseline, and higher than that where the BM BCR‐ABL mRNA ≥ 2 log‐reductions (P < 0.001). A strong correlation (r = 0.811, P < 0.001) was only found where the BM BCR‐ABL mRNA < 1 log reduction. We conclude that the differences and correlations of BCR‐ABL mRNA between PB and BM assays depend on the depth of the molecular response in BM for CML during imatinib therapy. Am. J. Hematol., 2012.


16 December 2019 in Research Square
Verified
Preprint
Open access
WWWei Wang
Wei Wang
YLYan Li
Yan Li
LMLan Ma
Lan Ma
WHWen-Qing Hu
Wen-Qing Hu
BJBin Jiang
Bin Jiang
Background We detected the expression of CD25 in patients with acute myeloid leukemia (AML) to value whether CD25 could be a promising marker for minimal residual disease (MRD). Methods Two hundred and twenty bone marrow (BM) specimens from 98 adult patients with AML after chemotherapy were detected using flow cytometry. The expression of CD25 was compared between MRD positive and negative subgroups. Results About 38% of patients with MRD were positive for CD25. The mean percentage of CD25-positive cell subpopulation was 58.68% relative to the whole MRD cluster (0.05%-100%). The mean fluorescence index ratio (MFIR) of CD25 in these cell subpopulations was approximately13-fold greater than that in normal myeloblasts. The detection sensitivity of CD25 was as high as 10 -4 . CD25 was also expressed on non-leukemic stem cells that were positive for CD34 and CD38. Conclusion CD25, as assessed by flow cytometry, is a promising marker for MRD in patients with AML.